Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme at BAP conference Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme at BAP conference By matt.poulter|2022-08-02T18:51:31+00:00August 2nd, 2022| Read More
Stratified medicine company Monument Therapeutics announces the start of its first clinical study for MT1980, a novel treatment for neuroinflammation Stratified medicine company Monument Therapeutics announces the start of its first clinical study for MT1980, a novel treatment for neuroinflammation By matt.poulter|2022-06-13T08:39:19+00:00June 13th, 2022| Read More
We are attending the BIO Conference: join us at two exciting sessions We are attending the BIO Conference: join us at two exciting sessions By matt.poulter|2022-06-07T09:06:30+00:00June 7th, 2022| Read More
Our CEO Jennifer Barnett is featured in The Guardian in an important article discussing the critical impact of postoperative cognitive dysfunction (POCD) Our CEO Jennifer Barnett is featured in The Guardian in an important article discussing the critical impact of postoperative cognitive dysfunction (POCD) By matt.poulter|2022-05-02T10:56:58+00:00May 2nd, 2022| Read More
Our CSO Dr Kiri Granger is listed as one of In Vivo’s 2022 ‘Rising Leaders’! Our CSO Dr Kiri Granger is listed as one of In Vivo’s 2022 ‘Rising Leaders’! By matt.poulter|2022-04-26T18:22:28+00:00April 26th, 2022| Read More
Our CEO Jennifer Barnett will be speaking at the Neuroimmunology Drug Development Summit, taking place next week in Boston, MA Our CEO Jennifer Barnett will be speaking at the Neuroimmunology Drug Development Summit, taking place next week in Boston, MA By matt.poulter|2022-04-11T09:02:21+00:00April 11th, 2022| Read More
Stratified medicine company Monument Therapeutics to present positive preclinical data for anti-neuroinflammation target MT1980 at AD/PD conference Stratified medicine company Monument Therapeutics to present positive preclinical data for anti-neuroinflammation target MT1980 at AD/PD conference By matt.poulter|2022-03-15T07:10:28+00:00March 15th, 2022| Read More
Stratified medicine company Monument Therapeutics to announce development of novel risk prediction tool for post-operative cognitive decline at AD/PD conference Stratified medicine company Monument Therapeutics to announce development of novel risk prediction tool for post-operative cognitive decline at AD/PD conference By matt.poulter|2022-03-15T07:07:08+00:00March 15th, 2022| Read More
Stratified medicine company Monument Therapeutics raises additional £0.5 million to take anti-neuroinflammation candidate MT1980 into clinic Stratified medicine company Monument Therapeutics raises additional £0.5 million to take anti-neuroinflammation candidate MT1980 into clinic By matt.poulter|2021-12-14T14:51:25+00:00December 14th, 2021| Read More
Monument Therapeutics collaborates with the University of Nottingham on pioneering schizophrenia study Monument Therapeutics collaborates with the University of Nottingham on pioneering schizophrenia study By matt.poulter|2021-09-21T16:59:36+00:00September 21st, 2021| Read More
